Making Molecular Delivery
Effortless, Efficient & Targeted

Conventional drug delivery is not efficient enough because of specific structural characteristics of the cell membrane, which makes it highly selective and impermeable to many molecules. But even when a therapeutic has successfully penetrated a cell, only less than 2% of the drug will escape the early endosomes to reach its intended intracellular target. Thus, to get the desired effect, we must use higher doses of the drug and this, in turn, can cause fierce dose-dependent side effects.

GEENIE

is Superior

Our novel delivery platform, GEENIE, a proprietary engineered biomolecule, selectively translocates directly through the cell membrane, avoiding the endosomes, manages to efficiently deliver molecular cargos of different sizes. This allows us to strongly decrease administration dosage and use up to 40 percent less drug, greatly reducing drug toxicity. Also, the negative charge of our molecule makes it highly tolerable to immune system. All this makes GEENIE a potent yet safe carrier platform to target and deliver therapeutic molecules to specific cells.

Non Endocytic Cell Entry

Non-toxic and Non-Immunogenic (In vitro and In mice)

Targeted Drug Delivery

(GBM & HER2+)

Dose Reduction

Non Endocytic Cell Entry

Targeted Drug Delivery

(GBM & HER2+)

Non-toxic and Non-Immunogenic (In vitro and In mice)

Dose Reduction

PIPELINE

Our main market targets are therapies against HER2 positive breast cancer and glioblastoma. While there is an approved effective treatment against HER2 positive breast cancer, the current market is valued at $10.4 billion, and it is expected to grow. Modern glioblastoma treatment efforts result in a short median survival of approximately 15 months, which leaves the treatment market highly unsatisfactory. The global glioblastoma drug market is expected to reach $2.3 billion by 2029. We are certain that our novel platform is a strong competitor to the currently available drug delivery systems.

Indication /
Cargo

  • Glioblastoma
  • HER2 positive
    breast cancer
  • Biologics (SiRNA, ASO, CRISPR cas, mRNA)

Candidate
Selection

Lead
Optimization

Pre Clinincal
development

IND Application

1st in
human trial

Orphan drug designation(ODD)

granted by USFDA (July 2023)

View In Landscape Mode

Non Endocytic Cell Entry

Non-toxic and Non-Immunogenic (In vitro and In mice)

Targeted Drug Delivery

(GBM & HER2+)

Dose Reduction

CyFect CRISPR Guard

CyFect CRISPR Guard

CRISPR/Cas9 is an efficient and inexpensive gene-editing tool that can accurately modify specific regions of DNA. The technology is now widely used in biomedical research to create novel therapies for various diseases, including cancers and rare genetic disorders. The system is rather bulky, it consists of two key molecules that have to be specifically translocated into cells. Successful intracellular delivery of this system is crucial in the progression of this revolutionary technology to allow for its implementation in clinics.

CyGenica has developed CyFect CRISPR Guard: a novel molecule that delivers gene-editing machinery to target cells with a delivery rate 40% higher than the one currently used. We are developing a strategy to improve the genome editing rates to bring the CRISPR system closer to its adoption in modern medicine.

CyGlo

Live cell imaging is a challenging method that allows visualization and monitoring of living cells over time under a microscope. Special reagents are needed to allow for accurate distinction of different cell compartments. Cell staining for live cell imaging is a demanding process since the available reagents are toxic and have low staining efficiency. This results in a low survival rate and poor visualization quality.

CyGlo is a non-toxic cell labelling reagent that efficiently crosses the living cell membrane without damaging it, staining 90% of the cells in just 1 hour. The reagent is available in targeted forms, specifically labeling desired intracellular compartments e.g. nucleus and mitochondria.

Our Gallery

© 2024️ CYGENICA. ALL RIGHTS RESERVE